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Abstract: Brg1 (Brahma-related gene 1) is one of two mutually exclusive ATPases that can act as the
catalytic subunit of mammalian SWI/SNF (mSWI/SfigureNF) chromatin remodeling enzymes that
facilitate utilization of the DNA in eukaryotic cells. Brg1 is a phospho-protein, and its activity is
regulated by specific kinases and phosphatases. Previously, we showed that Brg1 interacts with and
is phosphorylated by casein kinase 2 (CK2) in a manner that regulates myoblast proliferation. Here,
we use biochemical and cell and molecular biology approaches to demonstrate that the Brg1-CK2
interaction occurred during mitosis in embryonic mouse somites and in primary myoblasts derived
from satellite cells isolated from mouse skeletal muscle tissue. The interaction of CK2 with Brg1
and the incorporation of a number of other subunits into the mSWI/SNF enzyme complex were
independent of CK2 enzymatic activity. CK2-mediated hyperphosphorylation of Brg1 was observed
in mitotic cells derived from multiple cell types and organisms, suggesting functional conservation
across tissues and species. The mitotically hyperphosphorylated form of Brg1 was localized with
soluble chromatin, demonstrating that CK2-mediated phosphorylation of Brg1 is associated with
specific partitioning of Brg1 within subcellular compartments. Thus, CK2 acts as a mitotic kinase that
regulates Brg1 phosphorylation and subcellular localization.
Keywords: Brg1; SMARCA4; casein kinase 2; phosphorylation; mitosis; chromatin remodeling
enzyme; cell proliferation; myoblasts
1. Introduction
The mammalian SWI/SNF (SWItch/Sucrose Non-Fermentable; mSWI/SNF) complexes belong
to a family of chromatin-remodeling enzymes that utilize ATP to modify chromatin structures and
DNA/histone contacts [1–3]. These chromatin remodelers can either promote or inhibit the accessibility
of various factors that control gene transcription, replication, recombination, and repair [4–6].
The enzymatic activity of the mSWI/SNF complexes are driven by the ATPase Brahma-related
gene 1 (Brg1) or Brahma (Brm) [2,7–9]. There are many associated subunits that combine in an
ordered manner [10] to form different subfamilies of complexes that contain both common and unique
subunits [10–14]. The great diversity of enzyme complex assemblies is thought to enable cell- and
developmental stage-specific functions [14,15].
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We and others have shown that the activity of Brg1 and other components of the mSWI/SNF
complex is post-translationally regulated by various signaling pathways [16–22]. For instance, in the
liver, BAF60c phosphorylation via the insulin-signaling pathway enables the expression of lipogenic
genes [23]. In cardiac muscles, the DPF/BAF45c subunit is phosphorylated in response to hypertrophic
signaling [19]. The catalytic subunit Brg1 is phosphorylated upon DNA-damage signaling by the ataxia
telangiectasia-mutated kinase, resulting in the binding of the ATPase to nucleosomes containingγ-H2AX
to enable repair centers [24]. In Drosophila, where there is only one catalytic subunit, phosphorylation
by cyclin-dependent kinases is needed for cell proliferation and development of wing epithelium [25].
Studies of skeletal muscle differentiation showed that the BAF60c subunit is phosphorylated by the
mitogen-activated protein kinase p38, which allows the assembly of the rest of the mSWI/SNF complex
at myogenic promoters [18,26]. mSWI/SNF enzymes are required for myoblast proliferation and at
multiple stages of differentiation [27–32]. Regulated phosphorylation and dephosphorylation of Brg1
is an essential part of both proliferation and differentiation [16,17,22]. Phosphorylation of Brg1 by
protein kinase C β1 (PKCβ1) prior to the induction of differentiation signaling has a repressive effect on
the function of Brg1 and leads to a block of myogenic differentiation [16]. However, dephosphorylation
of Brg1 by the phosphatase calcineurin opposes the activity of PKCβ1, allowing chromatin remodeling
by Brg1 and initiation of myogenesis [16]. Mutagenesis and unbiased mass spectrometry analyses of
Brg1 phosphopeptides in the presence and absence of a calcineurin inhibitor identified calcineurin
target sequences, but the mass spectrometry data identified additional Brg1 phosphopeptides that were
not responsive to calcineurin inhibition [16]. This suggests that Brg1 is a target of additional signal
transduction pathways. Our subsequent studies showed that Brg1 was phosphorylated by casein
kinase 2 (CK2), a serine/threonine kinase, which promoted myoblast proliferation and survival by
regulating subnuclear localization and incorporation of one of two related subunits, BAF155/BAF170,
into the enzyme complex [17].
CK2 is ubiquitously expressed and functions as a tetramer of two catalytic subunits, CK2α or
CK2α’, and two CK2β regulatory subunits, and it has more than 300 known substrates [33–35]. CK2 is
required for cell cycle progression, survival, apoptosis, and transcriptional regulation. Knockout
mice lacking the CK2α subunit show cardiac and neural tube defects and die during embryogenesis,
whereas mice lacking the α’ subunit have impaired spermatogenesis [36–38]. Knockout of the CK2β
subunit in mice leads to reduced proliferation during embryogenesis, which is reflected in the small
size of the animals at embryonic day 6.5 (E6.5) and resorption at E7.5 [39]. Analyses of a murine
conditional knockout model showed that CK2β is essential for viability of embryonic stem cells and
primary embryonic fibroblasts [39]. In vitro cell experiments have shown that CK2 inhibition results
in cell cycle blockage and death [40–43]. Thus, CK2 has been associated with proliferation, lineage
determination, and differentiation of various tissues, including skeletal muscle [44].
CK2-mediated regulation of myoblasts occurs at multiple levels. For instance, transcription
factors from the myogenic regulatory factor (MRF) family and paired box (Pax) 3 and 7 are directly
or indirectly regulated by CK2 activity [17,45–52]. These proteins are necessary for the proliferation
and/or differentiation of muscle-specific precursor cells [46,53–58]. In vivo studies showed that the
CK2α’-depleted mice have a similar muscular constitution as wild-type animals [38,59]. However,
these CK2α’ knockout mice showed altered regeneration of skeletal muscles due to the dysregulation
of the cell cycle, which resulted in muscle fibers of reduced sizes [59]. Furthermore, muscles of mice
depleted of the CK2β subunit presented with compromised muscle endplate structure and function,
and consequently, the differentiated fibers showed a myasthenic phenotype [60]. In vitro studies
using C2C12 cells showed that each of the CK2 enzyme subunits contributed to the determination
of the skeletal muscle lineage. CK2β contributed to myoblast commitment and muscle-specific gene
expression, as it is essential for MyoD expression in proliferating myoblasts [61]. CK2α was required
for the activation of the muscle-specific gene program [61]. CK2α’ regulated myoblast fusion by
facilitating membrane translocation of fusogenic proteins, such as myomixer [61].
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Previous work from our group showed that Brg1 is required for the proliferation of primary
myoblasts derived from mouse satellite cells, because it binds to and remodels chromatin at the Pax7
promoter and activates its expression [28]. Pax7 is the master transcriptional regulator for proliferation
of the muscle satellite cells [62–65]. Pax7 knockout mice have a reduced pool of satellite cells that are
gradually lost with age, impairing the animal’s capabilities to regenerate muscle tissues [53,54,57,66].
We showed that overexpression of Pax7 in primary myoblasts lacking Brg1 rescues the cells from
apoptosis and restores proliferation, indicating that Brg1 regulates Pax7 expression to promote primary
myoblast survival and proliferation [28]. Furthermore, we showed that Brg1 is phosphorylated by CK2
in proliferating primary myoblasts and that CK2 inhibition impaired Brg1 chromatin remodeling and
transcriptional activity at the Pax7 locus [17]. In addition, phosphorylation of Brg1 by CK2 correlated
with the subunit composition of the mSWI/SNF enzyme complex and its subnuclear localization [17].
Here, we report novel findings about Brg1 phosphorylation by CK2. We found that co-localization
between CK2 and Brg1 occurred only in cells undergoing mitosis in developing somites of mouse
embryos and in primary myoblasts isolated from satellite cells. Co-immunoprecipitation from primary
myoblasts in M phase confirmed the association of Brg1 with CK2. The interaction between CK2
and Brg1, or other mSWI/SNF subunit proteins in mitotic cells, was independent of CK2 enzymatic
activity, whereas localization to soluble chromatin required CK2 enzymatic function. Importantly,
CK2-dependent hyperphosphorylation of Brg1 was conserved across different cell lineages. We note
that prior work showed phosphorylation of Brg1 during M phase by extracellular signal-regulated
kinases (ERKs) [67,68], which therefore indicates multiple protein kinases act on Brg1 during mitosis.
2. Results
2.1. Brg1 and CK2 Co-Localize in Mitotic Cells in Developing Somites of Mouse Embryos
Work from our group and many others have demonstrated that CK2 is implicated in myoblast
function [17,45–52,59–61]. Specifically, we demonstrated that CK2 modulates the ability of Brg1 to
promote myoblast proliferation by inducing Pax7 expression [17]. To corroborate our studies in vivo,
we investigated the interaction between CK2 and Brg1 in murine embryonic somite development.
Somites are fast-dividing paired blocks of paraxial mesoderm that are the source of the sclerotome,
myotome, and dermatome, which give rise to bone, muscle, and the dermis, respectively. Confocal
microscopy analyses confirmed that Brg1 and CK2 are expressed in somitic cells from E9.5 mice
(Figure 1). As expected, Brg1 localization was nuclear, and CK2 localization was predominantly, but not
exclusively, cytoplasmic. Strikingly, little or no co-localization between these proteins was detected in
interphase cells; however, clear co-localization of Brg1 and CK2 was detected in mitotic cells (Figure 1;
lower panel, white arrows). Mitotic cells were marked by the detection of condensed chromosomes
stained with phosphorylated histone H3 (PHH3). In order to further investigate the Brg1-CK2
interaction during the progression of mitosis, we used an in vitro model of cultured primary myoblasts
derived from mouse satellite cells. Images of mitotic cells from an asynchronous cell population were
collected, with staining by PHH3 to mark the different stages of mitosis. Co-localization between Brg1
and CK2 was observed first at prometaphase and continued until late-telophase (Figure 2).
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Figure 1. Casein kinase 2 (CK2) and Brahma-related gene 1 (Brg1) co-localize in mitotic cells of
developing somites in mouse embryos. Representative confocal microscopy images from mice embryos
showing the expression of Brg1 (green), CK2 (red), and phosphorylated histone H3 (PHH3, yellow) in
somites of embryonic day 9.5 (E9.5) mice. The nuclei were stained with DAPI (blue). The white arrow
in the upper panel points to the area of enlargement in the lower panels. The white arrows in the lower
panel point to mitotic cells. Three different embryos were analyzed.
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Figure 2. CK2 and Brg1 co-localize in mitotic primary myoblasts derived from mouse satellite cells.
Representative confocal microscopy images from three independent biological replicates show the
expression of Brg1 (green), CK2 (red), and phosphorylated histone H3 (PHH3, yellow) in proliferating
primary myoblasts. The nuclei were stained with DAPI (blue).
2.2. Pharmacological Inhibition of CK2 Activity Does not Impair Its Interaction with Brg1
To facilitate biochemical studies of mitotic cells, we treated cycling primary myoblasts with
nocodazole, a commonly used inhibitor of microtubule polymerization that results in cell cycle arrest at
mitosis [69]. Flourescence-activated cell sorting (FACS) analysis of control or treated cells demonstrates
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the enrichment in the G2/M population that was obtained in the presence of nocodazole (Figure 3A).
Our previous study addressed the effects of the specific CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole
(TBB) [70] on the proliferation capabilities of primary myoblasts derived from satellite cells and on
the properties of Brg1 and the mSWI/SNF complex in treated cells [17]. We again made use of TBB
to determine whether the CK2-Brg1 interaction required the enzymatic activity of CK2. Reciprocal
co-immunoprecipitations showed that in control and in nocodazole-synchronized mitotic myoblasts,
Brg1 and CK2 interacted as expected (Figure 3B). The interaction was maintained even when CK2 was
inhibited by TBB (Figure 3B), demonstrating that the enzymatic activity of CK2 is not necessary for the
formation of a stable complex containing Brg1 and CK2.
Figure 3. Inhibition of CK2 enzymatic activity does not impair its interaction with Brg1 or affect
the interaction of Brg1 with numerous mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF)
complex proteins. Primary myoblasts were treated or not with 500 nM nocodazole and 10 µM
tetrabromobenzotriazole (TBB). (A) Representative fluorescence-activated cell sorting (FACS) analyses
of primary myoblasts treated or not with nocodazole. (B) Representative Western Blots from a reciprocal
immunoprecipitations of Brg1 (left panel) or CK2 (middle panel). IgG inputs (IPs) and input (1%) for
both proteins are shown as controls. (C) Representative Western Blots of Brg1 immunoprecipitation and
Western Blots for the mSWI/SNF subunits BAF155, BAF60c, BAF57, BAF47, and BAF60a. IgG and inputs
(2%) for all samples were included as controls. Three independent biological replicates were performed.
2.3. CK2 Inhibition Does not Impair the Interaction of Brg1 with Additional Subunits of the
mSWI/SNF Complex
We next asked whether the interaction of Brg1 with other mSWI/SNF subunits was dependent on the
enzymatic activity of CK2. Immunoprecipitation assays for Brg1 from control and nocodazole-treated
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myoblasts showed a co-immunoprecipitation of Brg1 with BAF155, BAF60c, BAF57, and BAF47 in the
presence or absence of TBB (Figure 3C). BAF60a, a homolog of BAF60c that is poorly or not incorporated
in mSWI/SNF complexes in skeletal muscle [71], was used as a negative control (Figure 3C). These
data indicate that CK2 enzymatic activity is not required for the association of the indicated subunits
with Brg1. The data do not address whether the different subfamilies of mSWI/SNF complexes contain
all known components in the presence of TBB; however, the data suggest that mSWI/SNF enzyme
complexes are not prevented from forming because of the inhibition of CK2 enzymatic activity.
2.4. Brg1 is Hyperphosphorylated by CK2 during Mitosis
Though we have provided numerous lines of evidence for CK2-mediated phosphorylation of
Brg1 [17], there is an expectation that hyperphosphorylation of Brg1 might be visible in a Western
Blot. However, this has been complicated by the large size of the Brg1 protein, the large number
of identified and potential phosphorylation sites on Brg1, and the diversity of kinases that act or
might be predicted to act on Brg1. Definitive evidence of hyperphosphorylation due to CK2 in
conventional SDS-PAGE has been elusive. Therefore, we chose to use Phos-Tag™-supplemented
SDS-PAGE. Phos-Tag™ forms alkoxide-bridged dinuclear metal complexes that bind to phosphorylated
proteins and enhance changes in the migration of phosphorylated proteins [72–74]. Figure 4A shows
a Western Blot of nocodazole-synchronized cells where Brg1 migrated more slowly than Brg1 from
TBB-treated and control cells. Determination of the relative electrophoretic mobility of Brg1 showed that
the reduced migration observed in samples obtained from mitotic-enriched myoblasts was significant
compared to the nontreated controls (Figure 4B). These data suggest an enrichment of CK2-mediated
phosphorylation of Brg1 during mitosis. In vitro assays of Brg1 from nocodazole-treated cells showed
that treatment with calf-intestinal alkaline phosphatase (CIP) increased the mobility of Brg1 in a
Phos-Tag™ gel (Figure 4C; compare lanes 1 and 4). Addition of EDTA-chelated metals required for
CIP activity prevented the increase in gel mobility, as expected (Figure 4C; lanes 1–4). Addition
of purified CK2 restored the shift in mobility of Brg1 but not in the presence of TBB (Figure 4C;
compare lanes 5 and 6). Quantification of the relative mobility of Brg1 in each sample is presented in
Figure 4D, and the change in mobility due to changes in the phosphorylation state was statistically
significant. The combination of approaches taken in Figure 4 demonstrates the dependence of the
altered electrophoretic mobility of Brg1 on the catalytic activity of the CK2 kinase.
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Figure 4. Brg1 is phosphorylated by CK2 during mitosis. Primary myoblasts were treated or not with
500 nM nocodazole and 10 µM TBB, as indicated. Samples were separated in a 5% SDS-PAGE
supplemented with Phos-Tag™. (A) Representative Western Blot of the CK2-mediated shift in
Brg1 mobility in myoblast cultures enriched for mitotic cells. PI3K levels were monitored as a
loading control. (B) Quantification of the average relative mobility of Brg1 in the gel in response
to nocodazole treatment and CK2 inhibition (n = 3). (C) Representative Western Blots following an
in vitro dephosphorylation/phosphorylation assay on Brg1 in primary myoblast extracts from cells
treated as indicated. β-actin was monitored as a control. (D) Quantification of the average relative
mobility of Brg1 in the gel in response to the treatments indicated in (C) (n = 3). (E) Representative
Western Blots showing no easily discernible changes in mobility for BAF155, BAF60c, BAF57, or BAF47
in primary myoblast extracts from cells treated as indicated. PI3K was used as a loading control. Three
independent biological replicates were performed for each experiment. Statistical significance was
calculated by a t-test vs. the untreated control. * p < 0.05; ** p < 0.01.
We subsequently examined the mobility of the other subunits tested in Figure 3C on Phos-Tag™
gels. BAF155, BAF60c, and BAF57, but not BAF47, show two or more bands that are presumably due to
differential phosphorylation (Figure 4E). No easily discernable changes in gel mobility were observed
due to the presence of TBB. These data do not exclude the possibility that CK2 phosphorylates any of
these mSWI/SNF subunits, but the data do demonstrate that large mobility shifts such as that shown
by the CK2-dependent phosphorylation of Brg1 do not occur in these other subunits.
2.5. CK2 Phosphorylation of Brg1 during Mitosis is a Conserved Event in Different Mammalian Species
and Tissues
To determine whether the CK2-dependent phosphorylation of Brg1 during mitosis is part of a
skeletal muscle-specific regulatory mechanism or is more widespread, we examined other cell types
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arrested in mitosis. We tested Brg1 gel mobility in Phos-Tag™ gels using Madin-Darby canine kidney
(MDCK) epithelial cells, murine 3T3-L1 pre-adipocytes, murine C2C12 myoblasts, HeLa human cervical
cancer cells, and human mammary epithelial MCF10A cells. Each of these are immortalized cell
lines, in contrast to the primary cells tested in the experiments presented in Figures 1–4. HeLa cells
are a transformed cancer cell line. Representative Western Blots from Phos-Tag™ gels show that in
each cell type, Brg1 from cells grown in the presence of nocodazole migrated with reduced mobility,
in contrast to the mobility observed in control cells (Figure 5). β-actin levels were monitored as a
control. The reduced migration of Brg1 observed in samples enriched for mitotic cells was significant,
as shown by the calculation of relative mobility in each of these cell lines (Figure 5C–G). These results
suggest that CK2-dependent phosphorylation of Brg1 is a conserved event during mitosis of different
cell types originating from different mammalian species.
Figure 5. CK2-dependent phosphorylation of Brg1 in mitosis is a conserved event in different cell types
and species. (A) Madin-Darby canine kidney (MDCK), 3T3-L1, C2C12, HeLa, and MCF10A cells were
treated or not with cell type-specific concentrations of nocodazole, as indicated in Methods, and 10 µM
TBB where indicated. Samples were separated in a 5% SDS-PAGE gel supplemented with Phos-Tag™
for Brg1 blots or by conventional SDS-PAGE for β-actin. Representative Western Blots of the mobility
shift of Brg1 in extracts from cell cultures treated as indicated are shown, with β-actin expression from
the same samples shown as a loading control (B). (C–G) Quantification of the average relative mobility
of Brg1 in the gel in response to nocodazole treatment and CK2 inhibition of different cell lines. Three
or more independent biological replicates were performed for each experiment. Statistical significance
was calculated by a t-test vs. untreated controls. * p ≤ 0.05; ** p < 0.01.
2.6. CK2 Enzymatic Activity is Required for Proper Sub-Cellular Partitioning of Brg1
Nuclear fractionation experiments showed that Brg1 and other mSWI/SNF proteins are associated
with both soluble chromatin and the nuclear matrix [75,76], which is a nonchromatin fibrogranular
ribonucleoprotein network within the nucleus [77]. The nuclear matrix provides an anchoring structure
to chromatin loops, among other functions [78–80]. We previously demonstrated that Brg1 proteins
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containing phosphomimetic mutations at sites of CK2 activity lost the ability to associate with both
soluble chromatin and the nuclear matrix, whereas Brg1 containing alanine substitutions at sites of CK2
activity that prevented phosphorylation associated only with the nuclear matrix [17]. We investigated
the effects of CK2 inhibition on the localization of Brg1 in mitotic cells using a sequential extraction
protocol that generates a cytosolic fraction, a soluble chromatin fraction, and, after a high salt wash,
the nuclear matrix fraction [17,75,81]. A representative Western Blot of Brg1 from primary myoblasts is
shown in Figure 6A. The hyperphosphorylated, or lower mobility, form of Brg1 from mitotic myoblasts
was associated with the soluble chromatin fraction. In contrast, Brg1 associated with the nuclear matrix
showed no alterations in gel mobility in all the conditions tested (Figure 6A). Representative control
Western Blots showed the purity of the fractions (Figure 6B). Tubulin β was found in the cytosolic
fraction, lamin β1 localized to the nuclear matrix, and RNA pol II was located in the soluble chromatin.
The data indicate that Brg1 phosphorylated by CK2 in mitotic cells is associated exclusively with the
soluble chromatin and is not associated with the nuclear matrix.
Figure 6. CK2-mediated phosphorylation of Brg1 is associated with soluble chromatin. Primary
myoblasts were treated or not with 500 nM nocodazole and 10 µM TBB. (A) Representative Western
Blots showing the sub-nuclear localization of Brg1. Samples were separated in a 5% SDS-PAGE gel
supplemented with Phos-Tag™. (B) Representative Western Blots demonstrating the purity of the
fractions presented in (A). Tubulin is a marker for the cytosolic fraction, RNA Polymerase (Pol) II,
the soluble chromatin fraction, and Lamin β1, the nuclear matrix fraction. Three independent biological
replicates were performed for each experiment.
3. Discussion
3.1. Identification of CK2 as an M Phase Kinase for Brg1 Conserved across Mammalian Species and
Tissue Types
Post-translational modification of proteins comprising the mSWI/SNF chromatin remodeling
enzymes is a mechanism to regulate function in addition to established mechanisms involving
expression level of subunits, mutation of subunits, and diversity in the composition of enzyme
complexes. We previously demonstrated that Brg1 is a substrate for CK2 that affects myoblast
proliferation [17]. In the current work, we noted that Brg1 and CK2 co-localized only in mitotic cells
in murine embryonic somites and in primary myoblasts derived from mouse satellite cells. These
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findings provide insight into the role of CK2-mediated phosphorylation of Brg1 by establishing that this
post-translational modification occurs during a specific phase of the cell cycle. We therefore altered our
experimental approach by enriching for a mitotic population of cells through addition of nocodazole,
which inhibits microtubule polymerization and therefore blocks the separation of mitotic chromosomes
during mitosis. This approach, in combination with the use of the Phos-Tag™ reagent [72–74], allowed
us to reproducibly visualize an altered (reduced) electrophoretic migration of Brg1 in mitotic cell extracts
for the first time. The dependence of this modification on CK2 was demonstrated by manipulation of
CK2 activity in cells and in vitro, providing visual evidence of CK2-mediated phosphorylation of Brg1
to complement mutagenesis studies previously published [17]. Some of the other mSWI/SNF subunits
also were examined for CK2-dependent altered electrophoretic mobility. Although multiple forms of
several of those proteins were evident in the Western Blots, consistent with the established observation
that most, if not all, of the mSWI/SNF proteins are phosphoproteins [82], there was no obvious effect of
CK2 inhibition. This suggests that CK2 primarily targets Brg1 but does not exclude the possibility that
other mSWI/SNF proteins are also modified.
Given that this work and our prior work examined the phosphorylation of Brg1 by CK2 in primary
murine myoblasts derived from satellite cells, which are adult stem cells that promote post-natal
skeletal muscle expansion and repair, it was important to ascertain whether this event was restricted to
post-natal skeletal muscle or not. The co-localization of CK2 with Brg1 in mitotic mouse somites does
not demonstrate CK2-mediated phosphorylation of Brg1 in embryonic tissue, but it is suggestive of
function during embryonic development. More conclusive data was obtained by surveying a small
assortment of cell lines for CK2-dependent phosphorylation of Brg1. Canine and human, in addition
to murine cells, showed evidence of CK2-dependent phosphorylation of Brg1 in mitosis. The cell lines
tested were derived from several different tissue types, and one was derived from a human tumor.
Thus, we observed phosphorylation of Brg1 in mitotic primary, immortalized, and transformed cells
from different tissue types. These results suggest conservation of function.
3.2. The Role of CK2 as a Kinase for Brg1 during Mitosis
The experiments presented here indicate that CK2 catalytic activity is not required for Brg1 and
CK2 to associate, based on reciprocal co-immunoprecipitation experiments, and is also not required
for Brg1 to associate with at least some of the other mSWI/SNF subunits in a complex. Evidence
to date indicates a functional role for CK2 in myoblast proliferation, as well as in differentiation
(reviewed above), likely due to the large number of CK2 substrates. The link between CK2-mediated
phosphorylation of the Brg1 ATPase of mSWI/SNF chromatin remodeling enzymes and function is to
date limited to myoblast proliferation, but the exact nature of this function remains unclear. Previously,
we depleted primary myoblasts of endogenous Brg1 by introduction of Cre recombinase into primary
myoblasts isolated from a Brg1 conditional mouse [83] and showed that myoblast proliferation and
survival was compromised [28]. We then engineered a system to replace the endogenous Brg1 in
such myoblasts with wild-type or mutant Brg1 to make functional assessments of specific Brg1 amino
acids [16,17]. When we mutated predicted sites of CK2 activity on Brg1 by substituting glutamine
to introduce phosphomimetic amino acids, myoblast proliferation and survival was compromised,
as in the case of Brg1 depletion or introduction of catalytically inactive Brg1 [17]. Substitution with
alanine to introduce nonphosphorylatable amino acids had no effect on rate of proliferation or survival,
while inhibition of CK2 activity with TBB actually increased myoblast proliferation rate, suggesting
that phosphorylation of Brg1 by CK2 negatively impacted proliferation and that a balance between
phosphorylation and dephosphorylation at sites of CK2 activity is required for normal cell proliferation.
In the current work, we noted that CK2-mediated phosphorylation of Brg1 occurs in mitosis and
that hyperphosphorylated Brg1 partitions with the soluble chromatin, not with the nuclear matrix.
Our prior study showed that inhibiting CK2-mediated phosphorylation did not impact the ability
of Brg1 to bind to and remodel chromatin at the Pax7 promoter in support of Pax7 gene expression
and that Brg1 was restricted to the nuclear matrix under these conditions [17]. The results therefore
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suggest that CK2-mediated phosphorylation of Brg1 is not required for transcription-related functions,
at least at the Pax7 locus. Instead, a Brg1 function related to the role of soluble chromatin during
mitosis seems more likely. Does regulated CK2-mediated phosphorylation of Brg1 facilitate mitotic
chromatin condensation? Or might the phosphorylation state of Brg1 be related to its ability to
contribute to higher-order genome organization in the nucleus? Knockdown of Brg1 in proliferating
MCF10A breast epithelial cells resulted in altered nuclear shapes [84], altered telomere organization,
and a weakening of topologically associating domain (TAD) boundaries [85], implicating Brg1 as a
necessary component for proper genome organization and nuclear structure [86,87]. Three-dimensional
genome organization observed in interphase cells is profoundly altered in mitosis [88] via mechanisms
involving condensin-mediated organization of chromatin loop arrays [89]. Perhaps CK2-mediated
phosphorylation of Brg1 contributes to or is a consequence of this process. Precise identification of
the exact Brg1 amino acids that are phosphorylated by CK2 would further our understanding and
promote additional experimentation to explore their functions.
3.3. CK2 and ERK Modifications of Brg1 during Mitosis
Early work on the mSWI/SNF complex determined that most, if not all, of the subunit proteins were
phosphoproteins [82], that Brg1 was a mitotic phosphoprotein [90], and that hyper-phosphorylation of
Brg1 occurred during mitosis [67,68]. The hyperphosphorylation of Brg1 during mitosis was correlated
with the dissociation of Brg1 from the condensing mitotic chromosomes [67,68]. Dephosphorylation
of Brg1 was associated with the reassociation of BRG1 with chromatin as cells exited mitosis [67].
The mSWI/SNF complex purified from mitotic cells was inactive in in vitro chromatin remodeling
assays, while mSWI/SNF complexes purified from cells exiting mitosis were active [67]. The kinase
responsible for this activity has been investigated in vitro. Cdc2-cyclinB kinase did not phosphorylate
Brg1 or other mSWI/SNF subunits [90]. However, a purified, active mSWI/SNF complex isolated from
HeLa interphase cells could be treated with ERK1, a member of the mitogen-activated kinase (MAPK)
family, resulting in Brg1 hyperphosphorylation and the inactivation of the chromatin remodeling
activity of the mSWI/SNF complex. The data suggest that a MAPK phosphorylates Brg1 as a switch to
control its chromatin remodeling activity and that the chromatin remodeling activity is inactivated as a
cause or consequence of Brg1 exclusion from the condensing mitotic chromosomes.
The intersection of these data with the data presented about CK2-mediated phosphorylation of
Brg1 is limited to two points. First is the observation that Brg1 was found associated with one or more
other mSWI/SNF enzyme subunits in mitosis [67,68] (Figure 3). Thus, many of the mSWI/SNF enzyme
subunits remain in a complex during mitosis, apparently regardless of the phosphorylation state of
Brg1. Second, observations about Brg1 phosphorylation from each of the studies directly indicate or at
least suggest that they are conserved across different tissue types and, likely, across species [67,68]
(Figure 5). Though it is possible that either CK2 or MAPK could be sufficient for Brg1 phosphorylation
during mitosis, the predicted sites of MAPK and CK2 phosphorylation activity are different, making
it possible that different kinases act on Brg1 during mitosis. Whether kinases modifying Brg1 work
in concert or independently, and whether each promotes the same or different functions, remains
unknown. Nevertheless, the data collectively supports the concept that Brg1 and mSWI/SNF enzyme
functions are dynamically regulated by phosphorylation during mitosis.
4. Materials and Methods
4.1. Cell Culture
4.1.1. Murine Primary Myoblasts Derived from Satellite Cells
Mice were housed in the animal care facility at the University of Massachusetts Medical School
(Worcester, MA, USA) in accordance with the Institutional Animal Care and Use Committee guidelines.
Mouse satellite cells were purified from whole-leg muscle from 3- to 6-week-old male and female
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wild-type C57Bl/6 by differential plating following Percoll sedimentation, as previously described [91].
Isolated primary myoblasts were plated at 4 × 104 cells/cm2 in growth media (GM) containing a 1:1
mix of DMEM and F-12 media; 20% fetal bovine serum (FBS); 2% chick embryo extract; 25 ng/mL
recombinant basic fibroblastic growth factor (FGF, Millipore, Burlington, MA, USA); and 100 U/mL of
penicillin/streptomycin.
4.1.2. 3T3-L1 Murine Pre-Adipocytes
Cells were plated at 2 × 104 cells/cm2 and maintained at <50% confluency in DMEM with high
glucose, supplemented with 10% FBS and 100 U/mL of penicillin/streptomycin.
4.1.3. Human MCF10A Breast Epithelium Cells
Cells were plated at 1 × 105 cells/cm2 in a mixture of DMEM/F12 (1:1, v:v), supplemented with 5%
FBS, 100 U/mL penicillin/streptomycin, 0.5 µg/mL hydrocortisone, 10 µg/mL insulin, and 20 ng/mL
epidermal growth factor (EGF).
4.1.4. Murine C2C12 Myoblast Cells, Madin-Darby Canine Kidney (MDCK) Cells, and Human
Cervical Epithelial Adenocarcinoma HeLa Cells
Cells were plated at 1 × 105 cells/cm2 in DMEM, supplemented with 10% FBS and 100 U/mL of
penicillin/streptomycin.
Where indicated, the cells were cultured in the presence or absence of nocodazole to induce cell
cycle arrest in mitosis. The nocodazole concentrations and incubation times were: 500 nM for 16 h
for primary myoblasts obtained from C57Bl/6 mice and C2C12 cells [92], 300 nM for 16 h for 3T3-L1
preadipocytes [93], 250 nM for 24 h for MCF10A cells [94], 250 nM for 16 h for HeLa cells [95], and
100 nM for 11 h for MDCK cells [96]. CK2 was inhibited with 10 µM of TBB, as described before [17].
Media was replaced every day.
4.2. Antibodies
The primary antibodies used were: rabbit anti-CKIIα (2656), rabbit anti-BAF60c (62265), and rabbit
anti-phospho-histone H3 (Ser10; D2C8) conjugated to Alexa Fluor 647 and were obtained from Cell
Signaling Technologies. The rabbit anti-Brg1 (G-7), rabbit anti-BAF155 antibody (H-76), rabbit
anti-lamin β1 (H-90), and rabbit anti-pol II (N-20) were purchased from Santa Cruz Biotechnology.
The rabbit anti-PI3K p85 antibody, N-SH2 domain (ABS233), was obtained from Millipore Corp.
The rabbit anti-Ini1 (BAF47) antisera was previously described [29]. The rabbit anti-SMARCE1
(BAF57, A13353) and rabbit anti-SMARC1 (BAF60a, A6310) were obtained from Abclonal Technology.
The secondary anti-mouse and anti-rabbit horseradish peroxidase-conjugated antibodies and the Alexa
Fluor 488- and 555-conjugated antibodies were from Thermo Fisher Scientific.
4.3. Embryo Collection and Whole Mount Immunostaining
All animal experiments were conducted under the guidance of the Institutional Animal Care
and Use Committee of the University of Massachusetts Medical School. CD-1 mice were obtained
from Charles River Laboratories (Strain code 022). All animals were maintained on a 12 h light cycle.
The middle of the light cycle of the day when a mating plug was observed was considered embryonic
day 0.5 (E0.5) of gestation.
Embryos were collected at E9.5 and were fixed with phosphate-buffered 10% formalin overnight at
4 ◦C. The next day, the embryos were washed three times with PBS for 10 min and permeabilized with
PBT buffer (0.5% Triton-X100 in PBS) for 10 min at room temperature. Samples were incubated with
blocking solution for 1 h (PBT, 5% horse serum) at room temperature. The embryos were incubated with
the primary antibodies against CK2 and Brg1 (1:100) in blocking solution overnight at 4 ◦C. The samples
were then washed three times with PBT solution for 10 min at room temperature, then incubated
with species-specific fluorescent secondary antibody (1:500) in PBT for 2 h at room temperature and
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washed three times with PBT solution for 10 min at room temperature. Samples were incubated
with the anti-PHH3 antibody for 2 h at room temperature, followed by a 30 min incubation with
4′,6-diamidino-2-phenylindole (DAPI). Negative controls were prepared as described above, but no
primary antibodies were included. Embryos were washed three times with PBT at room temperature
for 10 min, and a final wash was performed with PBS for 10 min at room temperature. Embryos were
equilibrated with sequential 15 min incubations of PBS:glycerol solutions (1:1, 1:2) and mounted in
Vectashield containing DAPI (Vector Labs). Imaging was performed with a Leica TCS SP5 confocal
laser scanning microscope (Leica) using a 40×water immersion objective.
4.4. Primary Myoblast Immunofluorescence and Confocal Microscopy Analyses
Proliferating myoblasts for immunofluorescence were grown on glass-bottom CELLview
Advanced TC culture dishes (Grenier Bio-One, Kremsmünster, Austria). Cells were cultured in
the presence or absence of 10 µM TBB. Cells were fixed in phosphate-buffered 10% formalin, blocked
in PBT buffer containing 5% horse serum, then incubated overnight at 4 ◦C with the anti-CK2 and
anti-Brg1 primary antibodies diluted 1:100 in blocking buffer. Cells were washed three times with PBT
buffer and sequentially incubated for 2 h with fluorescent labeled antibodies (1:500 dilution in blocking
buffer). After three additional washes with PBT buffer, the cells were incubated with the anti-PHH3
antibody. Cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and imaged with a
Leica TCS SP5 confocal laser scanning microscope (Leica) using a 40×water immersion objective.
4.5. Cell Cycle Analyses by Flow Cytometry
Primary myoblasts were incubated with 500 nM nocodazole for 16 h. The cells then were washed
in PBS to remove all traces of serum. The cell concentration was adjusted to 2 × 106 cells/100 µL in
PBS, and 900 µL of 95% ethanol were added dropwise to the cells while vortexing gently. Cells were
stored at 4 ◦C for 24 h. Then the cells were pelleted by centrifugation at 2000× g, the ethanol was
removed, and samples were washed once with PBS, centrifuged again, and PBS was removed. The cells
subsequently were incubated for 20 min in the dark at 37 ◦C in 1 mL of propidium iodide (PI) staining
solution containing 900 µl PBS, 2mM MgCl2, 50 µL propidium iodide stock solution (1 mg/mL),
and 50 µL of RNase Stock Solution (1 mg/mL). Samples were analyzed by fluorescence-activated cell
sorting at the Flow Cytometry Core at the University of Massachusetts Medical School.
4.6. Western Blot Analyses
Proliferating primary myoblasts were washed with ice-cold PBS and solubilized with RIPA buffer
(10 mM PIPES, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate,
and 10% glycerol) containing Complete Protease Inhibitor. Protein samples (20–40 µg) were
prepared for SDS-PAGE by boiling in Laemmli buffer. The resolved proteins were electro-transferred
to PVDF membranes (Millipore, Burlington, MA, USA). The proteins of interest were detected
with specific polyclonal or monoclonal antibodies, as indicated in the figures, followed by the
species-appropriate peroxidase-conjugated antibodies (Thermo Fischer Scientific, Waltham, MA, USA)
and chemiluminescent detection (Tanon™High-sig ECL Western Blotting Substrate, Abclonal, Woburn,
MA, USA). All Western Blotting experiments were performed using samples from three independent
experiments. For the electrophoretic separation of phosphorylated proteins, samples were loaded
in 5% SDS-PAGE, supplemented with Phos-tag™ acrylamide (Wako, AAL-107) and 10 mM MgCl2,
as indicated by the manufacturer. Relative mobility of proteins in gels is usually calculated as the
ratio of the distance moved by the protein to the distance moved by the dye front. In our experiments,
it was necessary to maximize the migration of Brg1 to separate the differently phosphorylated forms.
Consequently, the dye front had run off the gel. We therefore standardized the electrophoresis by
running for 3.5 h at 120 volts and used the ratio of the distance moved by Brg1 relative to the bottom of
the gel.
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4.7. Immunoprecipitation
Cells were washed three times with ice-cold PBS and resuspended in lysis buffer (50 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and Complete Protease Inhibitor).
Cell extract (250 µg) was incubated in a rotating mixer for 2 h with the anti-Brg1 or anti-CK2 primary
antibodies at 4 ◦C, followed by an overnight incubation with Pure Proteome Protein A/G mix magnetic
beads (Millipore). Samples were washed as indicated by the manufacturer, and immunoprecipitated
proteins were eluted with freshly prepared IP buffer (10% glycerol, 50 mM Tris-HCl, pH 6.8, and 1 M
NaCl) by incubating for 1 h at room temperature on a rotating mixer. Samples were analyzed by
SDS-PAGE and Western Blot.
4.8. Brg1 Dephosphorylation and Phosphorylation Assays
Dephosphorylation assays were performed with calf intestinal alkaline phosphatase (CIP;
New England Biolabs). Briefly, 100 µg of total protein extract from proliferating myoblasts were
incubated with 1× CIP buffer in the presence or absence of 50 units of phosphatase at 37 ◦C for 1 h;
control experiments for CIP inhibition were performed simultaneously with 50 mM EDTA. Then the
phosphatase was heat-inactivated at 80 ◦C for 10 min and samples were further incubated with CK2 in
the presence or absence of the specific inhibitor tetrabromobenzotriazole (TBB, 10 µM) for 30 min at
30 ◦C. Reactions contained 50 units of CK2 (New England Biolabs, Ipswich, MA, USA), supplemented
with 1× CK2 reaction buffer (20 mM Tris-HCl, 50 mM KCl, 10 mM MgCl2, and pH 7.5) and with 200 µM
ATP, as previously described [17]. Protein samples were separated with 5% SDS-PAGE, supplemented
with Phos-Tag™ acrylamide, as described above.
4.9. Cell Fractionation
Cell fractionation was performed according to the high-salt isolation protocol [17,75,81]. Briefly,
proliferating primary myoblasts were washed with ice-cold PBS and extracted in cytoskeleton buffer
(CSK: 10 mM PIPES, pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA, 1 mM DTT,
0.5% (v/v) Triton X-100, and Complete Protease Inhibitor). The insoluble cytoskeletal fraction was
isolated by centrifugation at 5000× g for 3 min. Chromatin was then solubilized by DNase I digestion
(1 unit; New England Biolabs) in CSK buffer with Complete Protease Inhibitor for 15 min at 37 ◦C.
The samples subsequently were incubated in 0.25 M (NH4)2SO4 for 5 min at 4 ◦C and centrifuged
at 5000× g for 3 min. The pellet was washed with 2 M NaCl in CSK buffer for 5 min at 4 ◦C and
centrifuged. The nuclear matrix contained in this final pellet was solubilized in 8 M urea buffer.
Fractions were analyzed by SDS-PAGE and Western Blotting; antibodies against RNA polymerase II,
β tubulin, and lamin β1 were used as controls for purity of the fractions.
4.10. Statistics
All experiments were performed three or more times. The data are presented as the mean ± SEM
or SD, as indicated in the figures and legends. The statistical significance of quantified data was
determined by a two-tailed Student’s t-test. KaleidaGraph software version 5.4.3 (Synergy) was used
for all statistical analyses. p ≤0.05 was considered significant.
5. Conclusions
CK2 interacts with and phosphorylates the Brg1 chromatin remodeling enzyme during mitosis,
which modulates cell proliferation. Hyperphosphorylation of Brg1 during mitosis was conserved
in a range of mammalian cell types and the hyperphosphorylated form was localized in the soluble
chromatin. This work provides evidence that CK2 is a mitotic kinase that phosphorylates Brg1 and
regulates its sub-cellular localization and function.
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